Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as ...

Here, we trace RWE's remarkable evolution from its handwritten roots through technological breakthroughs, methodological advancements, and regulatory milestones that have collectively elevated ...

Despite these benefits, biosimilar medicines remain under-recognised and underused in many markets. Real-world uptake often ...

The CHMP recommends conditional marketing authorization for Duvyzat to treat Duchenne muscular dystrophy in patients aged 6 ...

WASHINGTON – The Trump administration ousted the director of the National Security Agency Thursday night, according to top congressional Democrats who decried the firing as making the U.S. less ...

At its April 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) gave ...

In addition, Eisai must conduct a post-authorization safety study, including setting up a patient registry for the European Union. Now each European country must set its own rules for access and ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

Acoramidis is an orally administered selective small molecule that stabilises transthyretin (TTR) by more than 90%. This ...

The Italian Medicines Agency is ready to evaluate the reimbursement of new drugs against obesity, following the British model ...

The company said that Vyvgart (efgartigimod alfa) is the first novel mechanism of action for CIDP treatment in more than 30 years.

The company expects the European Commission (EC) to make a final decision on the marketing authorization in June 2025.